Switch View
© Globe Newswire
05.11.2025
ISIN: DK0062498333
Novo Nordisk A/S
NOVO B
LISTED
CPH
Novo Nordisk's sales increased by 12% in Danish kroner and by 15% at CER in the first nine months of 2025; R&D pipeline progress continues
News Preview
Novo Nordisk's sales increased by 12% in Danish kroner and by 15% at CER in the first nine months of 2025; R&D pipeline progress continues...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
ISIN: US45256X1037
Immunitybio Inc
IBRX
LISTED
NASDAQ
Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024
News Preview
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced its financial results for the fiscal quarter and nine months ended September 30, 2025.
In the third quarter of 2025, ImmunityBio reported $31.8 million of product revenue, representing a 434% increase from $6.0 million in the third quarter of 2024. This growth refl...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2025
ISIN: US0021202025
Atyr Pharma, Inc.
ATYR
LISTED
NASDAQ
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Nov. 4, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of aTyr Pharma, Inc. (NASDAQ: A...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© PR Newswire
05.11.2025
ISIN: US0718131099
Baxter International, Inc.
BAX
LISTED
NYSE
BAX Investors Have Opportunity to Lead Baxter International Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Nov. 4, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Baxter International Inc. (N...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
05.11.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Nov. 4, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ:...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2025
ISIN: VGG111961055
Biohaven Ltd.
BHVN
LISTED
NYSE
FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia
News Preview
The troriluzole clinical development program encompassed the first industry clinical trials to generate data showing therapeutic potential in patients with spinocerebellar ataxia (SCA), a rare genetic, inherited, life-threatening neurodegenerative disease with no treatment options....
Themefolio
Profiler
Peergroup
© ACCESSWIRE
05.11.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
Evotec SE Reports 9M 2025 Results: Continued Strong Execution on Strategic Priorities
News Preview
Group revenues of € 535.1 m ((7.1)%); Discovery & Preclinical Development segment ("D&PD", (12.3)%) still sees soft demand;Just - Evotec Biologics ("JEB"; +11.3%) above-expectation; further accelerating growth on non-Sandoz / non-DOD businessStrong scientific advancements of co-developed asset pipeline: Expecting u...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: SG9999014716
WAVE Life Sciences Ltd
WVE
LISTED
NASDAQ
Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025
News Preview
Presentation will highlight preclinical data supporting the potential of WVE-007 (INHBE GalNAc-siRNA) as a unique approach for the treatment of obesity designed to drive fat loss while preserving muscle mass with once or twice annual dosing...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2025
ISIN: KYG4818G1010
Innovent Biologics Inc
1801
LISTED
HKSE
Multiple Research Results from Innovent's General Biomedicine Pipeline Showcased at 2025 ACR Annual Meeting
News Preview
SAN FRANCISCO and SUZHOU, China, Nov. 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology a...
Themefolio
Profiler
Peergroup
© PR Newswire
05.11.2025
ISIN: KYG0405D1051
Angelalign Technology Inc
6699
LISTED
HKSE
Angelalign Technology Expands Partnerships with Dexis™, Shining 3D, and Panda Scanner in iOrtho Release 5.3
News Preview
SAN CLEMENTE, Calif., Nov. 4, 2025 /PRNewswire/ -- Angelalign Technology Inc. (6699.HK) ("Angel") today announced the expansion of its flexible iOrtho® platform to include direct integration with the Dexis, Shining 3D, and Panda scanner. This new integration further strengthens iOrtho's open platform, which alrea...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
ISIN: KYG4672N1198
HUTCHMED (China) Ltd
13
LISTED
HKSE
HUTCHMED Announces Enrollment Completed of SAFFRON Global Phase III Trial of ORPATHYS® and TAGRISSO® Combination for Certain Lung Cancer Patients with MET Overexpression and/or Amplification After Progression on TAGRISSO®
News Preview
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces the completion of patient enrollment of SAFFRON, a global Phase III study of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) for the treatment of patients with epidermal growth fact...
Themefolio
Profiler
Peergroup
© Newsfile
05.11.2025
ISIN: CA62858B1085
MyndTec Inc.
MYTC
LISTED
CSE
MyndTec Inc. Completes Seventh Tranche of Non-Brokered Private Placement
News Preview
Mississauga, Ontario--(Newsfile Corp. - November 4, 2025) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), a neurological treatment and rehabilitation medical technology company, is pleased to announce that it has closed the seventh tranche of its non-brokered private placement previously announced on January 30, 2025 (the "Offeri...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
04.11.2025
ISIN: US70805E1091
Pennant Group Inc
PNTG
LISTED
NASDAQ
Pennant Acquires Senior Living Communities in Idaho and Wisconsin
News Preview
EAGLE, Idaho, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies, announces two significant acquisitions that strengthen its presences in key markets....
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: CA24874B1085
dentalcorp Holdings Ltd.
DNTL
LISTED
TSX
Dentalcorp Announces Receipt of Interim Order and Update Regarding Proposed Acquisition by Investment Funds Affiliated with GTCR
News Preview
dentalcorp Holdings Ltd. (“Dentalcorp” or the “Company”) (TSX: DNTL), Canada’s largest and one of North America’s fastest growing networks of dental practices, today announced that the Supreme Court of British Columbia has granted Dentalcorp an interim order providing for the calling and holding of the special meeting of Dentalcorp securityholders...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US89422G1076
Travere Therapeutics Inc
TVTX
LISTED
NASDAQ
Travere Therapeutics to Participate at Upcoming Investor Conferences
News Preview
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences:
Guggenheim's 2nd Annual Healthcare Innovation Conference
Presenting on Tuesday, November 11, 2025, at 9:00 a.m. ET
Stifel 2025 Healthcare Conference
Wednesday, November 12, 2025
TD Cowen Immunology &...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US6707031075
Nuvalent Inc
NUVL
LISTED
NASDAQ
Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer
News Preview
Encore pivotal efficacy and safety data from the ARROS-1 trial also to be presented during poster session
CAMBRIDGE, Mass., Nov. 4, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targe...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
LNTH Deadline: LNTH Investors with Losses in Excess of $100K Have Opportunity to Lead Lantheus Holdings, Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Nov. 4, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lantheus Holdings, Inc. (NASDA...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US2307701092
Cumberland Pharmaceuticals, Inc.
CPIX
LISTED
NASDAQ
CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH
News Preview
NASHVILLE, Tenn., Nov. 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $8.3 million during the third quarter of 2025. Year-to-date revenues for the first...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: CA89788C1041
Trulieve Cannabis Corp
TRUL
LISTED
CSE
Trulieve Announces Notice of Redemption for All US$368 Million of its 8.0% Senior Secured Notes due 2026
News Preview
TALLAHASSEE, Fla., Nov. 4, 2025 /CNW/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced it has issued a notice of redemption for all of its outstanding 8.0% senior secured notes due 2026 (CUSIP: 89788CAD6...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: CA89788C1041
Trulieve Cannabis Corp
TRUL
LISTED
CSE
Trulieve Announces Notice of Redemption for All US$368 Million of its 8.0% Senior Secured Notes due 2026
News Preview
TALLAHASSEE, Fla., Nov. 4, 2025 /PRNewswire/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced it has issued a notice of redemption for all of its outstanding 8.0% senior secured notes due 2026 (CUSIP: 89...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US14149Y1082
Cardinal Health Inc
CAH
LISTED
NYSE
Cardinal Health Board of Directors Approves Quarterly Dividend
News Preview
DUBLIN, Ohio, Nov. 4, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on January 15, 2026 to shareholders of record at the close of business on Janu...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US00973Y1082
Akero Therapeutics Inc
AKRO
LISTED
NASDAQ
Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO)
News Preview
PHILADELPHIA, Nov. 4, 2025 /PRNewswire/ -- Berger Montague PC advises shareholders of Akero Therapeutics, Inc. ("Akero" or the "Company") about an investigation into the Company and members of its Board of Directors for potential breaches of fiduciary duties and violations of the federal securities laws....
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US40131M1099
Guardant Health Inc
GH
LISTED
NASDAQ
Guardant Health Announces Proposed Public Offering of Common Stock
News Preview
Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced the commencement of an underwritten public offering of $250.0 million of shares of Guardant Health’s common stock (the “common stock offering”). Guardant Health also intends to grant the underwriters a 30-day option to purchase up to an ad...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US40131M1099
Guardant Health Inc
GH
LISTED
NASDAQ
Guardant Health Announces Proposed $300.0 Million Offering of Convertible Senior Notes Due 2033
News Preview
Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced its intention to offer $300.0 million aggregate principal amount of convertible senior notes due 2033 (the “notes”) in a private offering (the “convertible notes offering”) to persons reasonably believed to be qualified institutional buyer...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US87990A1060
Tenaya Therapeutics Inc
TNYA
LISTED
NASDAQ
Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025
News Preview
Oral Presentation on Saturday to Highlight Interim Safety and Efficacy Results from the MyPEAK™-1 Phase 1b/2a Clinical Trial in Adults with MYBPC3-Associated Hypertrophic Cardiomyopathy...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US74051N1028
Premier Inc
PINC
LISTED
NASDAQ
Premier Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Premier, Inc. - PINC
News Preview
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Premier, Inc. (NasdaqGS: PINC) to an affiliate of Patient Square Capital. Under the terms of the proposed transaction, shareholders of Premier will receive $28.25 in cash for each share of Pr...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US71742Q1067
Phibro Animal Health Corp
PAHC
LISTED
NASDAQ
Phibro Animal Health Corporation Declares Quarterly Dividend
News Preview
The Board of Directors of Phibro Animal Health Corporation (Nasdaq: PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on December 17, 2025, to stockholders of record at the close of business on November 26, 2025.
About Phibro Animal Health Corporation
Phibro Animal Heal...
Themefolio
Profiler
Peergroup
© EQS Newswire
04.11.2025
ISIN: CH1243598427
Sandoz Group AG
SDZ
LISTED
XWSX
Sandoz boosts in-house biosimilars capabilities by signing agreement to acquire Just-Evotec Biologics EU SAS in Toulouse
News Preview
Sandoz Group AG
/ Key word(s): Agreement
Sandoz boosts in-house biosimilars capabilities by signing agreement to acquire Just-Evotec Biologics EU SAS in Toulouse 04.11.2025 / 22:05 CET/CEST
Acquisition will enable expansion of in-house development and manufacturing capabilities and provide Sandoz with own capabilities for the ......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.11.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
In a landmark industry transaction, Evotec signs agreement with Sandoz, resulting in payments potentially over US$ 650 m plus royalties
News Preview
In a landmark industry transaction, Evotec signs agreement with Sandoz, resulting in payments potentially over US$ 650 m plus royalties on portfolio of up to 10 biosimilar molecules
Transaction showcases Evotec’s unique capability enabling customers to produce biologics faster and at lower costs through its continuous manufacturing techn......
Themefolio
Profiler
Peergroup
© EQS Newswire
04.11.2025
ISIN: DE0005664809
Evotec SE
EVT
LISTED
XETR
In einer wegweisenden Transaktion unterzeichnet Evotec eine Vereinbarung mit Sandoz über potenzielle Zahlungen in Höhe von über 650 Mio. US$ zuzüglich Umsatzbeteiligungen
News Preview
In einer wegweisenden Transaktion unterzeichnet Evotec eine Vereinbarung mit Sandoz über potenzielle Zahlungen in Höhe von über 650 Mio. US$ zuzüglich Umsatzbeteiligungen an einem Portfolio von bis zu 10 Biosimilar-Molekülen
Die Transaktion unterstreicht Evotecs einzigartige Fähigkeiten Kunden durch ihre kontinuierliche Produktionsstechn......
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US2290503075
Cryoport Inc
CYRX
LISTED
NASDAQ
Cryoport Reports Third Quarter 2025 Financial Results
News Preview
Third quarter revenue increased 15% year-over-year to $44.2 million
Commercial Cell & Gene Therapy revenue increased 36% year-over-year to $8.3 million
Life Sciences Service...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US1143401024
Azenta Inc
AZTA
LISTED
NASDAQ
Azenta Life Sciences Partners with PRECEDE Foundation to Advance Early Detection of Pancreatic Cancer
News Preview
BURLINGTON, Mass., Nov. 4, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced a strategic partnership with the PRECEDE Foundation, an international, multi-institutional collaborative focused on early detection and prevention of pancreatic cancer. Azenta will provide secure storage of study samples i...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US92686J1060
Viking Therapeutics Inc
VKTX
LISTED
NASDAQ
Viking Therapeutics to Participate at Upcoming Investor Conferences
News Preview
SAN DIEGO, Nov. 4, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at two upcoming investor conferences. ...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US00857U1079
agilon health inc
AGL
LISTED
NYSE
agilon health Reports Third Quarter 2025 Results and Re-Establishes Full Year Outlook
News Preview
agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced results for the third quarter ended September 30, 2025 and provided a full-year 2025 outlook.
“In the third quarter we made tangible progress executing on our transformation initiatives while continuing to absorb...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US6412881053
Neuropace Inc
NPCE
LISTED
NASDAQ
NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
News Preview
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update.
Third Quarter 2025 Financial Highlights
Total revenue of $27.4 million, representing growth of 30% compared t...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US2183521028
Corcept Therapeutics Inc
CORT
LISTED
NASDAQ
Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update
News Preview
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended September 30, 2025.
Financial Results...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US92337F1075
Veracyte Inc
VCYT
LISTED
NASDAQ
Veracyte Announces Third Quarter 2025 Financial Results
News Preview
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the third quarter ended September 30, 2025.
“We delivered another outstanding quarter of testing revenue growth and adjusted EBITDA margin expansion, enabling us to raise both our revenue and profitability guidance,” said Marc Stapley, Verac...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US45257U1088
Immunome Inc
IMNM
LISTED
NASDAQ
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Immunome, Inc. (the “company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on Nov. 3, 2025, the Compensation Committee of the company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock optio...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US68218J1034
OmniAb Inc
OABI
LISTED
NASDAQ
OmniAb Reports Third Quarter 2025 Financial Results and Business Highlights
News Preview
OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and nine months ended September 30, 2025, and provided operating and partner program updates.
“Throughout the third quarter we continued to execute on our strategic initiatives while further demonstrating the value of our proprietary technology platform to a growing base o...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US38246G1085
GoodRx Holdings, Inc.
GDRX
LISTED
NASDAQ
GoodRx Reports Third Quarter 2025 Results
News Preview
GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading platform for medication savings in the U.S., has released its financial results for the third quarter of 2025.
Third Quarter 2025 Highlights
Revenue of $196.0 million
Net income of $1.1 million; Net income margin of 0.6%
Adjusted Net Income1 of...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US3755581036
Gilead Sciences Inc
GILD
LISTED
NASDAQ
Gilead Sciences to Present at Upcoming Investor Conferences
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:
UBS Global Healthcare Conference on Monday, November 10 at 11:00 AM Eastern Time
Jefferies Global Healthcare Conference in London on Wednesday, November 19 at 2:00 PM Greenwich Mean Time
Citi’s Global Healthcare...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US7599101026
KORU Medical Systems Inc
KRMD
LISTED
NASDAQ
KORU Medical Systems Announces Development Agreement for Innovation in Subcutaneous Immunoglobulin Infusion Systems
News Preview
KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use patient-centric large volume subcutaneous infusion solutions, today announced a development agreement with a global pharmaceutical company....
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US14167L1035
CareDx Inc
CDNA
LISTED
NASDAQ
CareDx Announces Third Quarter 2025 Financial Results
News Preview
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company — a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the third quarter ended September 30, 2025.
Third Quarter...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US5747951003
Masimo Corporation
MASI
LISTED
NASDAQ
Masimo Reports Third Quarter 2025 Results
News Preview
Masimo Corporation (Nasdaq: MASI) today announced its financial results for the third quarter ended September 27, 2025.
Third Quarter 2025 Results From Continuing Operations(1):
GAAP revenue of $371.5 million, representing 8.2% growth on a reported basis;
Non-GAAP revenue of $371.2 million, representing 7.6% growth on a constant currency basi...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US30161Q1040
Exelixis Inc
EXEL
LISTED
NASDAQ
Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update
News Preview
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones.
“In the third quarter of 2025, Exelixis gained momentum in the cabozantinib franchise and delivered on cr...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US4333131039
Hinge Health, Inc.
HNGE
LISTED
NYSE
Hinge Health reports third quarter 2025 financial results
News Preview
Hinge Health, Inc. (NYSE: HNGE) today announced financial results for the third quarter ended September 30, 2025.
“With healthcare costs rising dramatically, our mission to automate care delivery has never been more urgent,” said Daniel Perez, Co-Founder and CEO, Hinge Health. “This quarter we surpassed 1.5 million lifetime members, delivered yea...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US3847471014
Grail, Inc.
GRAL
LISTED
NASDAQ
GRAIL to Present at 7th Annual Wolfe Research Healthcare Conference
News Preview
MENLO PARK, Calif., Nov. 4, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the 7th Annual Wolfe Research Healthcare Conference on Tuesday, Nov. 18 at 10:00 a.m. ET. ...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US1710774076
Niagen Bioscience Inc
CDXC
LISTED
NASDAQ
Niagen Bioscience, Inc. Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook
News Preview
Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the third quarter of 2025.
Third Quarter 2025 Financial Highlights Compared to Prior Year Period
Total net sales increased 33% to $34.0 million, with Tru Niagen® sales of $26.0 million, up 44%.
Gross margin increased 100 basis points to 64.5%.
Sales and marketing ex...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US0311621009
Amgen Inc
AMGN
LISTED
NASDAQ
AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS
News Preview
THOUSAND OAKS, Calif., Nov. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2025.
"We delivered strong volume growth this quarter, reflecting the demand for our medicines and the impact we're having on...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US7665596034
Rigel Pharmaceuticals, Inc.
RIGL
LISTED
NASDAQ
Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update
News Preview
Third quarter 2025 total revenue of approximately $69.5 million, including record net product sales of $64.1 million and contract revenues from collaborations of $5.4 million
Generated $27.9 million of net income in the third quarter...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US64132R4048
MetaVia Inc
NRBO
LISTED
NASDAQ
MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek® 2025
News Preview
New Phase 1 PK Data
Support Once-Weekly Dosing; Clinically Meaningful Weight Loss Observed Without Dose Titration
DA-1726 Achieves Superior Lipid-Lowering Effects and Comparable Weight Loss to Pemvidutide in
Pre-clinical Mode...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US69366J2006
PTC Therapeutics Inc
PTCT
LISTED
NASDAQ
PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
News Preview
– Initiated US and EU launch of Sephience™ (sepiapterin) –
– Strong initial Sephience uptake with global revenue of $19.6M and 521 start forms in the US as of September 30 –
– Robust Q3 performance with total...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US45720N1037
Inhibrx Biosciences Inc
INBX
LISTED
NASDAQ
Inhibrx Announces Participation in Upcoming Scientific Conferences
News Preview
SAN DIEGO, Nov. 4, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, today announced it will be presenting at the following upcoming scientific conferences:...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US1167941087
Bruker Corp
BRKR
LISTED
NASDAQ
Bruker Announces Quarterly Common Stock Dividend and Preferred Stock Dividend
News Preview
Bruker Corporation (Nasdaq: BRKR, BRKRP) today announced that its Board of Directors (“Board”) has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company’s common stock, par value $0.01 per share (the “Common Stock Dividend”). The Common Stock Dividend will be paid on January 2, 2026 to stockholders of record...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US86150R1077
Stoke Therapeutics Inc
STOK
LISTED
NASDAQ
Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
News Preview
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today reported financial r...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US03969T1097
Arcturus Therapeutics Holdings Inc
ARCT
LISTED
NASDAQ
Arcturus Therapeutics to Attend Upcoming Investor Conferences
News Preview
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that the Company will participate in the following investor conferences:
Guggenheim 2nd Annual He...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US71535D1063
Personalis, Inc.
PSNL
LISTED
NASDAQ
Personalis Reports Third Quarter 2025 Financial Results
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2025. The quarter was distinguished by significant operational momentum in its "Win-in-MRD" strategy, headlined by increasing clinical tests delivered and robust clinical evidence generat...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US6047491013
Mirum Pharmaceuticals Inc
TKOMF
LISTED
OTC
Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
News Preview
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the third quarter 2025 and provided a business update.
“Mirum is well positioned heading into 2026 with strong commercial momentum and multiple upcoming catalysts,” said Chris Peetz, Chief Executive Officer of Mirum. "Our third quarter results once again underscore th...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US0162551016
Align Technology, Inc.
ALGN
LISTED
NASDAQ
Align Technology to Speak at Upcoming Financial Conferences
News Preview
Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that the company is scheduled to speak at upcoming financ...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US88023B1035
Tempus AI, Inc.
TEM
LISTED
NASDAQ
Tempus Reports Third Quarter 2025 Results
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended September 30, 2025.
Revenue grew 84.7% year-over-year to $334.2 million in the third quarter of 2025
Gross profit reached $209.9 million in the third quarter of 20...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
